A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Ocellaris Pharma, Inc.
Bolt Biotherapeutics, Inc.
Actym Therapeutics, Inc.
NuCana plc
NRG Oncology
Sotio Biotech Inc.
Novartis
Novartis
Pfizer
ADC Therapeutics S.A.
Fate Therapeutics
Fate Therapeutics
Genmab
Nektar Therapeutics
Duke University
Calithera Biosciences, Inc
MacroGenics
Eli Lilly and Company
Cambridge University Hospitals NHS Foundation Trust
Seagen Inc.
Yale University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mayo Clinic
Celldex Therapeutics
Calando Pharmaceuticals
National Cancer Institute (NCI)
National Cancer Institute (NCI)